Bio Logbook joins the French Healthcare BOOSTER GERMANY.
Bio Logbook has been selected to take part in the French Healthcare BOOSTER GERMANY 2024, an acceleration program dedicated to French healthcare companies looking to expand in Germany.
This selection recognizes our expertise in digital solutions for clinical trial management and our strong growth potential in the German market.
A new stage in Bio Logbook's international expansion
A customized support program
The French Healthcare BOOSTER GERMANY 2024 will enable us to benefit from 9 months of tailor-made support. During this program, we will have access to :
- Individual support from coaches and experts in the German market.
- Training courses and workshops to better understand the German market and the specificities of its healthcare system.
- Connections with potential partners, such as investors, customers and institutional players.
A springboard for international business
We are convinced that the French Healthcare BOOSTER GERMANY 2024 will be a valuable springboard for our development in Germany. This program will enable us to :
- Accelerate our international growth.
- Strengthen our presence in the German market, one of the largest in Europe.
- Identify new partnership and collaboration opportunities.
We're proud to be part of this adventure alongside other innovative companies in the healthcare sector.
Together, we'll be helping to promote French know-how in Germany and improve patient health.
Live from Bio Logbook.
Find out about our latest news, collaborations and study projects.
NephroGuard has been selected as one of the Unirein Third-Party experimentation projects.
Bio Logbook reaches a major milestone with the publication of a ground-breaking study in the journal CCA Clinica Chimica Acta.
